Pursuing Professionalism, Together
Encouraged by their peers in other European nations, German licensing executives have organized a professional group to promote discussion of deal structures, trends, best practices, etc. Members hope the network will improve the probability of their own dealmaking, and perhaps also improve the level of professional experience in a country that now has many small biotech firms.
You may also be interested in...
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.